Angiomirs expression profiling in diffuse large B-Cell lymphoma

Autor(es):Mostrar menos -

Borges, Natalia M. ^[1] ; do Vale Elias, Marcela ^[1] ; Fook-Alves, Veruska L. ^[1] ; Andrade, Tathiana A. ^[1] ; de Conti, Marina Lourenco ^[1] ; Macedo, Mariana Petaccia ^[2] ; Begnami, Maria Dirlei ^[2] ; Campos, Antonio Hugo J. F. M. ^[2] ; Etto, Leina Yukari ^[1] ; Bortoluzzo, Adriana Bruscato ^[3] ; Alves, Antonio C. ^[4] ; Young, Ken H. ^[5] ; Colleoni, Gisele W. B. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Paulo, Dept Oncol Clin & Expt, Sao Paulo - Brazil

^[2] AC Camargo Canc Ctr, Sao Paulo - Brazil

^[3] Insper Inst Educ & Res, Sao Paulo - Brazil

^[4] Univ Fed Sao Paulo, Dept Patol, Sao Paulo - Brazil

^[5] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 - USA

• Tipo de documento: Artigo Científico
• Fonte: ONCOTARGET; v. 7, n. 4, p. 4806-4816, JAN 26 2016.
• Citações Web of Science: 8

Resumo

Despite advances in treatment, 30% of diffuse large B-cell lymphoma (DLBCL) cases are refractory or relapse after chemoimmunotherapy. Currently, the relationship between angiogenesis and angiomiRs in DLBCL is unknown. We classified 84 DLBCL cases according to stromal signatures and evaluated the expression of pro-and antiangiomiRs in paraffin embedded tissues of DLBCL and correlated them with microvascular density (MVD). 40% of cases were classified as stromal-1, 50% as stromal-2 and 10% were not classified. We observed increased expression of proangiomiRs Let-7f, miR-17, miR-18a, miR-19b, miR-126, miR-130a, miR-210, miR-296 and miR-378 in 14%, 57%, 30%, 45%, 12%, 12%, 56%, 58% and 48% of the cases, respectively. Among antiangiomiRs we found decreased expression of miR-16, miR-20b, miR-92a, miR-221 and miR-328 in, respectively, 27%, 71%, 2%, 44% and 11%. We found association between increased expression of proangiomiRs miR-126 and miR-130a and antiangiomiR miR-328 and the subtype non-GCB. We found higher levels of the antiangiomiRs miR-16, miR-221 and miR-328 in patients with low MVD and stromal-1 signature. IPI and CD34 confirmed independent impact on survival of the study group. None of the above angiomiRs showed significance as biomarker in an independent serum samples cohort of patients and controls. In conclusion, we confirmed association between antiangiomiRs miR-16, miR-221 and miR-328 and stromal-1 signature. Four angiomiRs emerged as potential therapeutic targets: proangiomiRs miR-17, miR-210 and miR-296 and antiangiomiR miR-20b. Although the four microRNAs seem to be important in DLBCL pathogenesis, they were not predictive of DLBCL onset or relapse in the serum independent cohort. (AU)

• Processo FAPESP: 10/17668-6 - Identificação de marcadores tumorais e possíveis alvos terapêuticos em doenças linfoproliferativas de células B
• Beneficiário: Gisele Wally Braga Colleoni
• Modalidade de apoio: Auxílio à Pesquisa - Temático